Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients

NCT01415674 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01415674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01415674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
December 31, 2021
Enrollment
61 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck